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The present study describes the effect of plasma exchange or whole blood exchange (PEBE) on 
the survival rate among patients with fulminant meningococcal sepsis and on the level ofcirculat-
|
ing endotoxin. Since 1989 all patients with meningococcal disease and hypotension who were 
admitted to our intensive care unit were treated with PEBE. Results for our patients were com­
pared with those for a historical control group conventionally treated between 1984 and 1989 
(//=1(): mortality rate, 60%); the expected mortality rate, which was based on the Niklasson 
prognostic score and was calculated for seven patients in this control group, was 73%. A total of
15 patients were treated with PEBE, three (20%) of whom died, whereas the prognostic score 
(calculated for 14 patients) for this group was 62%. In two of the fatal cases, PEBE was started 
after a delay of 2*40 hours. In the remaining 13 patients, PEBE was started within 5-30 hours 
after the first hospital admission. The mortality rate among this group was 8% (one of 13 pa­
tients); this rate was significantly different from that among the control group (P= .025). For 
seven patients treated with PEBE, plasma endotoxin concentrations were sequentially measured. 
The overall half-life (± SEM) of endotoxin was 181 ± 18 minutes. This is approximately the 
same as reported values for patients who were not treated with PEBE. It is concluded that early 
initiation of PEBE may improve the rate of survival among patients with meningococcal infec­
tion and hypotension but that the mechanism of the beneficial effect is most likely not based on 
the elimination of endotoxin.
Neisseria meningitidis invading the bloodstream can lead 
to different disease manifestations | I ]. After a 1- to 2-day 
flulike illness, acute meningitis may develop with signs o f  
meningeal inflammation without shock. The mortality rate 
associated with this disease is ~  1*7 [2]. On the o ther hand, in 
patients with fulminant meningococcal sepsis (FMS), severe 
shock develops within a few hours, often with diffuse intra- 
vascular coagulation; signs o f  meningeal inflammation are 
m inor or absent. The  mortality rate associated with FMS is
m r
high, varying from 30rr to 7 ()fr, even if intensive treatment is
C  4 -
started immediately [2-6].  Approximately  90fr o f  all fatal 
cases o f  FMS occur in patients who present with hypotension 
[2. 7]. According to most studies [8-1 2 ] ,  o ther signs o f  a poor 
prognosis on admission are the absence o f  meningeal inflam­
mation. the presence o f  rapidly extending hemorrhagic skin 
lesions, hyperpyrexia, leukocytopenia, thrombocytopenia, 
hypofibrinogenemia. diffuse intravascular coagulation, m eta­
bolic acidosis, and  rapid clinical deterioration. Multifactorial 
s c o r i n g  systems, com bining the above-m entioned  factors,CT J  ^
have been developed to predict ou tcom e and to distinguish 
patients who merit intensive or. in severe cases, even experi­
mental treatment |7, 8 , 10. 12]. In severe cases o f  FMS, it has 
been suggested that plasma exchange (PE) or whole blood 
exchange (BE) in addition to s tandard therapy reduces m or­
tality [13-16],  possibly bv accelerating the elimination o f  
endotoxin [ 1 7].
For editorial response, see pages 4 3 1 -3 .
In the last decade, the proportion o f  patients with FMS in 
the Netherlands has steadily increased, and  since 1989 the 
incidence o f  all meningococcal infections has doubled. In 
view o f  the poor results o f  conventional treatm ent in the 
preceding years, in 1989 we began to perform PE or BE 
(PEBE) in addition for patients with hypotension due to me- 
n i n gococca 1 i n fee t i o n .
In the present paper, we describe our  experience with 
PEBE and com pare the results o f  treatm ent with those for a 
historical control group o f  patients who were admitted  to the 
hospital before 1989. The changes in the concentrations of 
endotoxin during PEBE are also reported.
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Methods
From 1984 to 1992. 43 patients with meningococcal in­
fections were admitted to the intensive care unit (1C U ) o f  the 
University Hospital Nijmegen. O f  these patients, 27 pre­
sented with hypotension, w hich was defined as the following 
systolic blood pressures: adults, < 1 0 0  mm Hg: children < 4
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years old. < 7 5  mm I la; and children ^ 4  years old. < 85  mm 
I Ig. This latter group o f  27 patients will he discussed herein.
I he bacteriologie diagnosis was confirmed by culture o f  
CSF, blood, or specimens o f  skin lesions in 24 cases and  by 
serology in two. In one case culture results were lost, but theCV
diagnosis was clinically evident. Until 1989 10 patients were 
treated “ conventionally ,"  i.e.. with lluids. inotropic and va­
soactive druizs, antibiotics, steroids, mechanical ventilation, 
and, if necessary, hemodialysis or peritoneal dialysis. In ad ­
dition to conventional treatment, two patients underwent 
con tinuous  arteriovenous hemoliltration (C'AVll). Since 
1 989 PEBE was performed or was intended to be performed 
for 15 patients. In each PE session. 3 0 -4 0  ml. o f  plasma per 
kilogram was exchanged with fresh frozen plasma. The pro­
cedure. which took 1.5 -2 .0  hours, was started as soon as 
possible after admission and  was repeated after I 2 hours and, 
if the condition o f  the patient was still critical, after 24 and 
48 hours. In children whose body weight was < 2 5  kg, BE was 
performed with 5 0 -6 0  ml. o f  whole blood per kilogram, fol­
lowing the same schedule. Each session took 0 . 6 - 1.5 hours.
For determ ination o f  concentrations o f  endotoxin , 2-mL 
plasma samples were taken in 5-mL pyrogen-free plastic vials 
(Falcon, Becton and Dickinson. Lincoln Park, NJ) con ta in ­
ing 50 U o f  pyrogen-free heparin per milliliter, centrifuged at 
200g for 10 minutes, and  stored at — 70°C  until assay. The 
concentra tion  o f  endotoxin  was measured with use o f  a chro- 
mogenic Limulus am ebocyte  lysate assay (KabiVitrum, 
Stockholm). For statistical analysis, a W ilcoxon 's  test and 
adjusted x : test were used. Log-linear regression was used to 
calculate the elimination kinetics o f  endotoxin.
Results
Characteristics and Prognostic Values at Admission
Eight patients were directly adm itted  to our K 'U, and 19 
were referred from local hospitals. Clinical and laboratory 
values at hospital admission and  their prognostic significance 
are listed in table 1. Patients I - 10 were treated conven tion­
ally, patients 11 and 12 underw ent C'AVH in addition to
overhydration. The delay in time to referral in the conven- 
tional treatment group was shorter than that in the PEBE 
group, but this difference was not significant {P =  .22) (see 
table 2 ).
Treatment and Outcome
The primary treatment o f  all referred patients was started 
in the referring hospital. Hence, there was no uniformity in 
the treatment during the first hospitalization. All patients, 
except patients 2 and 27. received pharmacological doses o f  
glucocorticosteroids on admission.
After arrival at our K 'U, patients 1-10 were conven tion­
ally treated; six o f  these patients died. One o f  the survivors 
(patient 8 ) underwent am putation  o f  three toes and finger­
tips and suffered from complete  sensorineural deafness.
Patients I I and 12 underwent ( 'A V 11 in addition to co n ­
ventional treatment and are included in the present series for 
the sake o f  completeness; one o f  these patients died. This 
patient was referred to our K'U after a delay o f  56 hours 
because o f  multiple organ failure (M O F),  anuria, and gan­
grene o f  both lower lei’s. ( AVI I was started after 74 hours.c  C
Four days later cerebral death was noted. In patient 12 
C'AVll was started 6 hours after the first hospitalization and 
continued  for 52 hours; this patient completely recovered.
In patients 13-27 PEBE was done or was intended to be 
done; three o f  these patients died. Patient 22 arrived at our 
K'U after a delay o f  I I hours and was noted to be in severe 
shock with metabolic acidosis (p l l .  7.27; bicarbonate con­
centration, 16.9 mmol/L; base excess concentration, —9.2 
m m ol/L),  diffuse intravascular coagulation (fibrinogen con­
centration. 840 mg/L; fibrinolytic split product concentra­
tion. 240 mg/L; platelet count, 22 X I0 9/L), and  acute renal 
failure (serum creatinine. 305 jumol/L). He died o f  internal 
bleeding due to an iatrogenic perforation o f  the subclavian 
vein shortly before the intended PE could be started. In pa­
tient 13 and 25. PE was started 40 and 74 hours, respec­
tively. after the first hospital admission because o f  technical 
problems and delayed referral. Both patients had been hypo­
tensive for >  12 hours before PE was started and at the time
conventional treatments and  patients 13-27 underwent o f  its initiation had severe MOF, probably with cerebral dam-
PEBE. as specified in table 2. All patients had skin lesions of 
abrupt onset (existing < 6  hours). Large, extending ecchy-
age. Al ter the presence o f  severe cerebral damage was estab­
lished and treatment was withdrawn, these patients died. In
moses that were >1 cm in d iameter were seen in all patients the 12 other patients, PEBE was started within 5 -3 0  hours
except 12 and 27; in these two, only small purpural lesions 
were observed. Median values o f  age, preclinical disease pe-
after the first hospital admission and within 2-1 3 hours after 
arrival at our ICU. All recovered without serious sequelae.
riod. blood pressure, leukocyte count in CSF, leukocyte but three needed plastic surgery for necrotic skin areas. Dur- 
coun t  in peripheral blood, platelet count, and concentra- ing the exchange procedure, no adverse effects were ob ­
served.
For seven patients the concentration o f  endotoxin was 
monitored during PEBE (figure I ). T he  endotoxin concen­
tration correlated with the clinical severity o f  disease. Plasma 
endotoxin concentrations decreased at a more-or-less con-
tions o f  bicarbonate, base excess, and fibrinogen are given in 
table 1. These values did not differ significantly between 
both groups {P ^  .22). O f  the 19 referred patients, 15 were 
referred within 12 hours because o f  progressive shock. Pa­
tients I I. 23, and 25 were referred after a delay o f  56, 26.
and 59 hours, respectively, because o f  shock, anuria, and stant rate during the first 18 hours. T he  half-life (t^; ±  SEM)
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Table 1. Patient characteristics on admission with prognostic significance.
Patient no.
Sex/age
(y)
Preclinical disease 
period (h)
Blood 
pressure 
(m m  Hg)*
Central
tem pera ture
(°C )
Leukocyter
count  
in CSF 
(X I06/L )
Leukocyte 
co u n t  in 
peripheral 
blood 
(X I09/L )
Platelet 
coun t  at 
0 and  4 hf 
(X 10 9/L )
C oncen tra t ions  o f
H C O j /b a s e  
excess 
(m  m ol/L )
F ibr inogen/  
fibrinolytic 
split products  
(m g /L )
1 F /0 14 5 0 /40 39.9 46 10.0 6 7 /6 7 12 .5 /—14.7 5 4 0 /7 0
2 F/0 2 xx/xx 38.3 13 3.3 151/— 1 1 .8 / - 1 4 .4 1 ,700/—
3 F/3 8 xx/xx 39.7 72 7.5 123/— 12.5 /— 1 1.8 ---/ ---
4 F/6 6 7 5 /6 0 --- 6 4.3 150/72 1 2 .4 / - 1 0 . 0 ---/ ---
5 M/8 16 6 0 /3 0 --- --- 14.6 56 /46 1 7 .6 /—7.2 1 ,380/180
6 E/1 1 9 85 /35 40.1 52 15.7 138/120 2 I . 3 / - 4 . 6 2 .2 9 5 / <  10
7 M /1 7 10 9 0 /7 0 39.5 --- 4.8 19/14 1 3 . 5 / -  1 1.2 4 5 0 /1 ,0 2 4
8 M / 2 1 25 8 0 /4 0 40.1 --- 14.6 6 8 /48 10 .7 /—9.7 1,355/855
9 M /23 15 xx/xx 39.0 40 7.5 3 9 /— 1 0 .5 / - 1 3 .5 < 6 0 0 / —
10 F / 3 1 20 9 0 /6 0 38.0 2400 24.5 173/161 1 7 .8 /—4.7 3 . 9 5 0 / c  10
1 -10 (m ed ian ) 9.5 12 6 8 /38 39.6 46 8.8 9 6 /6 7 1 2 .5 / - 1 0 . 6 1 ,318/—
1 1 F/17 6 5 0 / xx 40.6 240 4.1 5 5 /3 0 12.0/ - 10.0 9 0 0 /1 8 0
12 M /22 16 xx/xx 40.8 68 3.7 119/127 1 8 .5 /—4.7 4 . 5 0 0 / <  10
13 M /0 6 xx/xx 39.4 6 5.9 122/18 1 1.0/ —21.0 3 0 0 /3 3
14 E/I 3 70/xx 39.5 120 1 1.8 196/162 14 .0 /—5.9 3 .0 5 5 /<  10
15 F / l 7 6 0 /4 0 39.4 20 1 1.0 196/98 1 5 .9 /—6.2 ---/ ---
16 M /3 9 6 8 /35 41.8 175 2.8 192/82 14.9 /—8.3 230/>240
17 M /4 19 6 0 /4 0 --- 13 19.2 123/61 1 1 .6 / - 1 7 .8 1 ,565/20
18 E/5 16 8 0 /5 0 40.7 1 1 7.3 23 1 /2 1 2 13.3 /—9.1 3 , 7 3 2 / c  10
19 M/8 6 8 0 /5 0 41.2 14 3.3 114/85 19 . 0 / - 4 . 8 3,500/20
20 E/9 10 7 5 /4 0 40.0 3 2.5 6 6 /7 0 1 4 .2 / - 1 0 .2 1,665/55
21 M /I  1 7 7 5 /5 0 41.8 45 2.0 79/58 17 .0 /—5.0 1,465/50
22 M /I  1 2 7 5 /5 0 39.0 98 7.0 125/43 ---/ --- < 5 0 0 / 1 7 0
23 F/14 9 7 5 /3 0 40.2 --- 2.8 95/71 1 4 .0 / - 1 0 . 0 — /220
24 F / l  5 9 xx/xx --- 1370 21.4 122/65 1 1 . 5 / - 1 5 .5 1.800/65
25 M /15 12 9 5 /65 39.8 12 4.5 6 1 /3 8 1 1 . 0 / - 1 5 .0 6 5 0 /1 8 0
26 M / 2 1 23 8 5 /6 0 38.7 1250 15.3 122/66 2 1 .0 / - 1 .7 4.1 1 5 / <  10
27 F/3  3 18 xx/xx 38.7 4250 18.0 189/105 18 .9 /—4.6 4 ,5 1 5 / <  10
13-27  (m ed ian) 9 9 7 5 /4 0 39.8 33 7.0 122/70 14. 1/ —8.7 1665/—
NOTE. Patients I- 10 were conventionally treated, patients I I and 12 underwent CAVH in addition to conventional treatment, and patients 13-27 were 
treated with PEBE. —  = missing values.
* xx/xx indicates that blood pressure was unmeasurably low. 
f Time calculated from (first) hospital admission.
ranged from 77 ±  3 minutes for patient 18 to 245 ±  27 
minutes for patient 14. On the basis o f  the assumption that 
kinetics were similar for all seven patients, the overall ty was 
181 ±  18 minutes. An accelerated decrease in endotoxin 
concentrations during the tirst PEBE session was observed 
for only four o f  seven patients.
Discussion
T he  present study describes the course and ou tcom e o f  
meningococcal infection in patients with hypotension who 
were treated with PEBE.
Hypotension is considered to be one o f  the most reliable 
and  strong predictors o f  a poor prognosis in meningococcal 
disease [2]. G ard lund  [7] reported a mortality rate o f  42% 
am ong  patients (all ages) who were admitted  with a systolic
blood pressure o f  <  100 m m  Hg [7]. Using more strict criteria 
for hypotension in children ( < 7 0  mm Hg for children 
younger than 12 or 14 years o f  age), o ther authors reported 
mortality rates varying from 19% to 53% am ong  hypotensive 
patients [2 , 8 , 18]. In this studv, we have defined hypoten­
sion as a systolic blood pressure o f  <  100 mm Hg in adults [2,
7, 8], < 7 5  mm Hg in children < 4  years o f  age, and  < 8 5  mm 
Hg in children ^ 4  years o f  age [ 10, 12]. It should be kept in 
mind, however, that the systolic blood pressure can remain 
nearly normal for a long time even in the presence o f  severe 
shock, especially in children.
The presence o f  more factors predicting a poor prognosis 
increases the chance o f  a fatal outcome. According to Niklas- 
son et al. [8 ], unfavorable prognostic features on admission 
are (1) the absence o f  meningitis (leukocyte count in CSF, 
< 1 0 0  X 10b/L), (2) the presence o f  hypotension (systolic
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Table 2. C o u rse ,  t r e a tm e n t ,  a n d  o u t c o m e  for all pa t ien ts .
Patient no.
Delay in 
time to 
referral** (h)
T rea tm en t  
(no. o f  sessions)
T im e  to 
start o f  
first PEBE 
after 
adm iss ion1 (h)
O u tcom e 
(t ime to 
dea th)
Expected mortality 
rate according 
to Niklasson 
score*
1 --- C onven t iona l Died (4 h) 88%
2 3 C onven t iona l Died (4 h) 88%
3 2 C onventiona l Died (4 h) 88%
4 3 C onven t iona l Died (14 h) Not evaluable
5 6 C onven t iona l Survived Not evaluable
6 --- C onven t iona l Survived 73%
7 10 C onventiona l Died (14 h) Not evaluable
8 --- C onventiona l Survived 88%
9 --- C onven t iona l Died (6 h) 88%
10 --- C onven t iona l Survived <73%
1-10 (m ed ian) 3
1 1 56 C onven t iona l  p lu s C A V H Died (7 d) 88%
12 1 C onven t iona l  p lu s C A V H Survived OC OC
13 6 PE (3) 40 Died (52 d) 88%
14 5 BE (2) 10 Survived <73%
15 24 BE (2) 30 Survived 88%
16 8 BE (3) 1 1 Survived 88%
17 --- BE (3) 6 Survived 73%
18 1 BE (2) 5 Survived 88%
19 12 PE (4) 16 Survived 88%
20 2 BE (1). PE (2) 15 Survived 88%
21 7 PE (3) 10 Survived 88%
22 1 1 Died (12 h) <73%
23 26 PE (3) 30 Survived 88%
24 3 PE (4) 5 Survived Not evaluable
25 59 PE (3) 74 Died (1 1 d) 88%
26 --- PE (3) 5 Survived <73%
27 --- PE (2) 5 Survived <73%
1 3 - 2 7  ( m e d i a n ) 7.5
* Bar ( — ) indicates directly adm it ted  to the ICU.
1 T im e  calculated from the first hospital admission.
* See [8],
blood pressure, < 1 0 0  mm Hg in adults and < 7 0  mm Hg in 
children up to 14 year old), (3) the presence o f  petechiae for 
< 1 2  hours, (4) hyperpyrexia (rectal temperature, > 4 0 °C ) ,  
( 5 ) the absence o f  leukocytosis (leukocyte count in blood. 
< 1 5  X 109/L), and ( 6 ) the presence o f  throm bocytopenia  
(platelet count, < 1 0 0  X 109/L). W hen three or four o f  the 
first four prognostic signs were present, the mortality was 
73%; the presence o f  four or five o f  the first five signs resulted 
in a mortality rate o f  88%. The individual prognoses o f  our 
patients’ conditions were based on this scoring system and 
are given in table 2 .
In our study, the observed mortality rate am ong the group 
treated conventionally  was 60% (6 o f  10 patients). This is 
approximately the same as the expected mortality rate calcu­
lated with use o f  the score o f  Niklasson. For seven patients 
this score could be calculated, and the expected mortality 
rate was 88% for five, 73% for one, and <73% for another.
Therefore, for this group the expected mortality was at least 
73% (5.13 o f  7 patients), and the observed mortality am ong 
this group was 57% (4 o f  7 patients).
In the literature, PEBE has been shown to reduce mortal­
ity. In 1979 Scharfman et al. [19] were the first to report a 
beneficial effect o f  PE for a patient with FMS. Meanwhile, 
24 cases o f  patients who were treated with PEBE or plasma­
pheresis and leukapheresis were reported; five ( 2 1%) o f  these 
patients died [13-16 ,  19, 20]. Despite the observation that 
PE had no beneficial effect in six dogs with Escherichia coli 
sepsis [2 1 ], several authors underlined the possible value o f  
this treatment for FMS [6 , 22]. However, no controlled stud­
ies are available, probably because o f  the rare incidence o f  
the disease and the inhomogeneity o f  clinical presentation. 
In this study, the mortality rate am ong the group treated with 
PEBE was 20% (3 o f  15 patients). For 14 o f  these patients, 
the expected mortality rate according to Niklasson could be
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endotoxin  (pg/m l)
hours a fte r firs t hospita l adm ission
Figure 1. Concentrations of endotoxin during the first 36 hours 
after the first hospital admission for eight patients (14, 16. 18. 19. 
2 1. 22. 24, and 26) treated with PEBE. PEBE sessions are indicated 
with dotted lines. Patient 22, indicated with a cross ( + ), died 
shortly after the first blood sampling, just before PE could be 
started. Abbreviation: p = patient.
calculated and was 62% (8.65 o f  14 patients), with an ob­
served mortality rate am ong  these patients o f  2 I t (3 o f  14 
patients).
PEBE is believed to be beneficial only when it is per­
formed during an early phase o f  the disease. In two patients 
in this study. PEBE was started > 4 0  hours after the initial 
admission. At that time, severe M O F and probably cerebral 
damage were already present. Alter the presence o f  extensive 
cerebral damage was established and treatment was with­
drawn, both patients died. Obviously, PEBE was started too 
late. T he  remaining 13 patients were treated or were in­
tended to be treated with PEBE within 30 hours after adm is­
sion. This group did not differ significantly from the histori­
cal control group with respect to the prognostic factors (see 
table 3). Yet, am ong  this group the observed mortality rate 
was only 8% (1 o f  1 3 patients) com pared with a mortality rate 
o f  60% am ong  the historical control group (P = .025) and  an 
expected mortality rate (calculated for 12 patients) o f  57% 
(6.89 o f  12 patients).
Some facts may have flattered these results. It is known 
that 70% o f  the patients with fatal cases died within 16 hours 
after admission [3 -5 ,  8 . 23, 24]. Table  3 shows that in the 
PEBE group more patients were referred and that the delay
in time to referral was longer. This may reflect patient selec­
tion, as dramatically ill patients died before referral was orga­
nized. Also, some o f  the o ther  prognostic factors summarized 
in table 3 show a slightly better prognosis for the PEBE 
group: however, none  o f  these differences were significant. 
Finally, the comparison with a historical control group may 
be criticized. Dagbjartsson and Ludvigsson [25] reported a 
lower mortality during the later phase o f  an epidemic possi­
bly because o f  better awareness o f  the public or trea tm ent by 
better-skilled doctors. Nevertheless, it is our impression that 
certain patients who were in deep shock at entry into our 
ICU clearly benefitted from PEBE. In the conventionally  
treated group, all patients w ithout leukocytosis (leukocyte 
count in blood, ^  10 X 109/L )  a n d /o r  a base excess co n cen ­
tration o f  ^ — 10.0 m m ol/L  died. In the PEBE group, eight o f  
nine patients with these poor prognostic signs survived. 
These figures support the conclusion that in patients with 
FMS early initiation o f  PEBE may improve outcom e, but 
clearly a controlled study is necessary.
We did not observe direct adverse effects o f  PEBE. H ow ­
ever, the risk o f  introducing a central venous catheter in a 
patient with shock and hemorrhagic diathesis should thor­
oughly be considered. Brandtzaeg et al. [14] reported the 
case o f  a patient who died after the retroperitoneal infusion 
o f  plasma because o f  the malposition o f  the femoral catheter. 
In our  series, cannulation  and perforation o f  the subclavian
Table 3. Presence of parameters with prognostic significance and 
outcome for patients who were treated conventionally and patients 
treated with early PEBE.
Parameter
Patients 
treated 
conventional ly  
(/» = 10)
Patients 
treated 
with early 
PEBE 
(// = 13) P value
Age (v. m e d ia n ) 9.5 9 .90*
Preelinical disease period (h. m edian) 12 9 .53*
Delay in time to referral (h, m edian) 3 7.5 .33*
Referred patients (no.) 5 /10 10/13 .37*
Fever ( tem perature .  Ss40°C) 2/8 6/1 1 .4 1+
Leukocyte coun t  in CSF.
< 1 0 0  X 10*7 L 6/7 7/12 .47*
Leukocyte count  in peripheral
blood, < 1 0  X 10 9/L 6/10 7/13 l .00+
Platelet count ,  < 1 0 0  X 109/L 5 /10 3/13 .37+
Bicarbonate concen tra t ion .
<  1 5 m m o l /L 7 /10 7/12 ,90+
Base excess concen tra t ion .
<—8 m m o l /L 7 /10 6/12 .61*
Fibrinogen concen tra t ion .
<  1,500 m g/L 5/8 3/1 1 .29*
Mortality
m
6/10 1/13 .025*
N O TE. Early PEBE is that started within 30 hours after  the first hospital 
admission.
* W ilco x o n ’s two-sample test.
1 Continui ty-ad jus ted  x 2 test.
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vein led to fatal bleeding in patient 22. Still, in most patients 
with severe shock, rapid access to a central vein is necessary 
for diagnostic and therapeutic purposes. On the basis o f  these 
experiences, we advise that in these cases venous catheteriza­
tion should be performed bv an experienced physician, pref- References 
erably into a compressible blood vessel.
Plasma endotoxin  concentra tions correlate with severity 
o f  the disease [ 19, 26]. We exam ined w hether an accelerated 
elimination o f  endotoxin  is responsible for the beneficial ef­
fect o f  PEBE. T he  elimination o f  endotoxin  during the first
I 8 hours was approximately  log-linear. In only four o f  seven 
patients, the elimination during the first PEBE session was 
increased com pared  with that during the period just before or 
after this session (figure 1). In this first 18 hours, the t j  o f  
endotoxin  (±  SEM ) for individual patients ranged from 77 ±
3 minutes to 245 ±  27 minutes. The  overall (±  SEM). 
which was calculated for all patients, was 181 ±  18 minutes.
This is in good accordance with the findings o f  Brandtzaeg et 
al. [20], who estimated a t^ o f  2 hours for 15 patients (o f  
whom  four were treated with PEBE) during the first 6 hours 
after admission and a o f  6 hours during the following pe­
riod. From these observations we conclude that an acceler­
ated elimination o f  endotoxin  is most likely not responsible 
for the im provem ent in the rate o f  survival.
We can only speculate about the beneficial mechanism o f  
PEBE. An alternative suggestion is the removal o f  proin- 
fiammatory cytokines such as tum or necrosis factor and in­
terleukin-1 ( IL-1) [15]. This mechanism has been d e m o n ­
strated in an experimental setting o f  E. co/i sepsis in piglets, 
where PE was started during an earlv stage o f  the disease 
[27]. In our group, however, such a mechanism is not proba­
ble, because tum or necrosis factor and IL-I are only detect­
able in the plasma during an early stage o f  the disease and 
disappear because o f  a short t^ [28]. A nother attractive hy­
pothesis is that PEBE stimulates the production o f  an ti in ­
flammatory cytokines. T he  addition o f  IgG to the plasma 
( 1 . 2 - 2 . 0  g/kg in the first 24 hours) may stimulate the pro­
duction o f  the IL-I receptor antagonist (IL-Ira). Such a 
theory is in accordance with recent findings that IgG im­
proves the survival rate am ong  patients with septic shock
[29], that IgG stimulates the production o f  IL-Ira, and that 
IL-1 ra improves the rate o f  survival after lethal endotoxem ia 
[30, 31 ]. In neonatal sepsis. BE is an accepted therapy [32].
O ur results support its performance in children and adults 
with meningococcal sepsis. The  beneficial mechanism o f  
PEBE. however, is unclear, and  the exact value o f  PEBE and 
its mode o f  action remain to be elucidated.
Westendorp for his fruitful contribution to discussions, 
W. A. G. Kraak for her help with the endotoxin assay, and 
A. k .  M. Bartelink for his critical reading o f  the manuscript.
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